Prevalence of Rifampicin Resistant Tuberculosis in four sentinel sites, The Gambia 2018.

  • Anti-microbial resistance
Export to CSV
Multidrug-resistant or Rifampicin-resistant tuberculosis (MDR/RR-TB) remains a threat to TB control and it is be- coming increasingly difficult to treat in some countries. In 2015, WHO estimated that of the 10.4 million cases of TB worldwide, 3.9% were MDR/RR-TB. In the Gambia, there is no information on the current prevalence of Rifampicin Resistant Tuberculosis from the four sentinel sites where TB treatment occurs. We conducted this study to deter- mine the prevalence of RR-TB from these sentinel sites.
We conducted a record review study in the four sentinel site for the period 2013-2018 in the Gambia. The Gambia has 7 regions and a population of 2,225,703. We reviewed and extracted data from national laboratory database where sensitivity test to the bacteria has been conducted. Variables extracted included disease status, age, sex, region, sensitivity test Results: and treatment status. Data was analyzed to determine frequencies, proportions, and rates.
Between 2013- 2018, a total of 1,350 sputum specimens were received from the four sentinel sites and analyzed for TB and Rifampicin resistance. 32.6% (441/1350) were mycobacterium Tuberculosis positive and out of which 7.0% (31/441) were Rifampicin-Resistant (RR-TB). Of the RR-TB, males were 65.2% (17/31) and the most affected age group was between 15-44years at 80.7% (25/31). Amongst the RR-TB, 48.3% (15/31) were bacteriologically confirmed and 19% (6/31) had HIV co-infection. Most of the cases peaked in 2015 with a RR-TB prevalence of 35%. Of the 7 regions in the country, the West Coast region had highest prevalence of 43.5%.
The prevalence of RR-TB was high and commoner in the West coast region of The Gambia. There is need for further studies to determine risk factors for RR-TB among TB patients undergoing treatment.

Please abstracts [at] tephinet [dot] org (email us) if you have any corrections.

If this abstract has been converted into a full article, please abstracts [at] tephinet [dot] org (email us) the link. We would love to help promote your work.